2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

654. Multiple Myeloma: Pharmacologic Therapies: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Genomics, Immune Mechanism, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

5790 Impact of daratumumab-lenalidomide maintenance versus observation according to MRD status in fit, transplant-ineligible patients with newly diagnosed multiple myeloma: Results from the phase III GEM2017FIT trial

Maria-Victoria Mateos Jr, MD, PhD, Bruno Paiva, PhD2, Noemi Puig, PhD3, Maria Teresa Cedena Romero, MD4, Anna Sureda5, Veronica Gonzalez-Calle, MD, PhD6, Albert Oriol Sr, MD7, Enrique Ocio Sr, MD, PhD8, Borja Puertas, MD, PhD9, Laura Rosiñol10, Yolanda González-Montes, MD11, Joan Bargay, MD, PhD12, Esther González García13, Sunil Lakhwani, MD, PhD14, Angel Ramirez15, Alexia Suarez Cabrera, MD16, María-Jesús Blanchard, MD17, Sebastián Garzón18, Luis Felipe Casado Montero19, Valentin Cabanas20, Jaime Perez De Oteyza, MD, PhD21, Mercedes Gironella Mesa22, Joaquin Martinez-Lopez Sr, MD, PhD23, Anabel Teruel24, Pilar Delgado25, Elena Prieto26, Juan-Jose Lahuerta Palacios, MD, PhD27, Joan Batista Blade Creixenti Sr, MD28, Jesus San-Miguel Sr, Md, PhD29
1 Hematology Department, Hospital Universitario de Salamanca-IBSAL, CIBERONC and Centro de Investigación del Cáncer, IBMCC (USAL-CSIC),, Salamanca, Spain
2 Hematology Department, Cancer Center Clinica Universidad de Navarra (CCUN), Cima, Idisna, CIBERONC, Pamplona, Spain
3 Hematology Department, Hospital Universitario de Salamanca-IBSAL, CIBERONC and Centro de Investigación del Cáncer, IBMCC (USAL-CSIC),, Salamanca, Spain
4 Hematology Department, Hospital 12 de Octubre, Medicine Department, Medicine School of Complutense University, I+12. CNIO, Madrid, Spain
5 Instituto Catalán de Oncología, L'Hospitalet De Llobregat, IDIBELL, Universitat de Barcelona, Barcelona, Spain
6 Hematology Department, Hospital Universitario de Salamanca-IBSAL, CIBERONC and Centro de Investigación del Cáncer, IBMCC (USAL-CSIC),, Salamanca, Spain
7 Clinical Hematology, Institut Català d’Oncologia and Josep Carreras Research Institute, Hospital Germans Trias I Pujol, Badalona, Spain
8 Hospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain
9 Hematology Department, Hospital Universitario de Salamanca-IBSAL, CIBERONC and Centro de Investigación del Cáncer, IBMCC (USAL-CSIC),, Salamanca, Spain
10 Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain
11 Institut d'Oncologia Dr. Josep Trueta, Girona, Spain
12 Hospital Universitario Son LLatzer, IdIsBa, Palma de Mallorca, Spain
13 University Hospital Cabueñes, Gijón, Spain
14 Hospital Universitario de Canarias, Tenerife, Spain
15 Hospital Universitario Central de Asturias, Oviedo, Spain
16 Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
17 Hospital Universitario Ramon y Cajal, Madrid, Spain
18 Hospital Universitario De Jerez, Jerez de la Frontera, Spain
19 Hospital Universitario Virgen de la Salud, Toledo, Spain
20 IMIB-Virgen de la Arrixaca University Hospital, Murcia, Spain
21 Universidad CEU San Pablo, Madrid, Spain
22 Hospital Universitari Vall d'Hebron, Barcelona, Spain
23 Hematology Department, Hospital 12 de Octubre, Medicine Department, Medicine School of Complutense University, I+12. CNIO, Madrid, Spain
24 Hospital Clínico Universitario de Valencia, Valencia, Spain
25 Hospital Universitario Miguel Servet, Zaragoza, Spain
26 Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
27 Hematology Department, Hospital 12 de Octubre, Medicine Department, Medicine School of Complutense University, I+12. CNIO, Madrid, Spain
28 Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain
29 Hematology Department, Cancer Center Clinica Universidad de Navarra (CCUN), Cima, Idisna, CIBERONC, Pamplona, Spain

Introduction

GEM2017FIT is a phase III trial in FIT transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). The primary endpoint was met, with KRd and D-KRd achieving significantly higher Minimal Residual Disease (MRD) negativity (10?5) rates than VMP9-Rd9 after induction (54%, 61%, and 27%, respectively). Following DRd consolidation, MRD negativity rates increased to 40% in VMP9-Rd9 arm, 56% in KRd, remained 61% in D-KRd.  This prespecified analysis evaluated the impact of  daratumumab plus lenalidomide (DR)  maintenance  on Progression Free Survival (PFS) according to MRD status.

 

Patients and Methods

This planned second-stage analysis evaluated whether DR maintenance prolonged PFS versus observation according to MRD status by EuroFlow Next Generation Flow (NGF) with a limit of detection of 10-5. Patients who completed induction and consolidation underwent a second randomization by MRD status to receive DR for 2 years followed by lenalidomide until disease progression or unacceptable toxicity, or observation.

Results

A total of 540 patients were screened, and 462 were initially randomized. Following induction and consolidation, 312 patients underwent a second randomization according to MRD status: 80 were MRD-positive and 232 MRD-negative. Among MRD-positive patients, 41 were assigned to daratumumab-lenalidomide (DR) maintenance and 39 to observation, whereas among MRD-negative patients, 116 were allocated to each strategy. Baseline characteristics were well balanced between the treatment arms within both MRD-defined subgroups.

After a median follow-up of 48 months from the second randomization, median PFS was 59.5 months in the observation arm and was not reached in the DR arm. At 5 years , 50% and 68% of patients, respectively, were alive and progression-free (HR 0.67, 95% CI 0.46–0.95; p=0.03). The effect of maintenance therapy was consistent across induction/consolidation strategies, with no evidence of interaction.

The treatment effect appeared more pronounced in the MRD-negative subgroup with 56% and 77% of patients, respectively, alive and progression-free at 48 months in the observation and DR arm, respectively (HR 0.62, 95% CI 0.38–1.03; p=0.06). In contrast, among MRD-positive patients, no statistically significant differences were observed between both arms, although the median PFS was numerically shorter in the observation arm, 30.3, versus DR maintenance arm, 45.2 months (HR 0.68, 95% CI 0.38–1.21; p=0.19).

In terms of toxicity, no new safety signals were reported with DR maintenance. Grade 3-4 neutropenia was the most frequent hematological adverse event observed in 26% of the patients although the incidence of G3-4 febrile neutropenia was reported only in 2 patients. 7% of patients reported G3-4 diarrea and G3-4 pneumonia was reported in 8.4% of patients; 16 patients (10.5%) developped other G3-4 infections. Only 4 patients discontinued DR because of toxicity. In the observation arm, G3-4 neutropenia occurred in 6.5% of the patients and 10 patients (6.5%) experienced G3-4 infections.

Overall, from the first randomization and after a median follow-up of 68 months, patients treated with Dara-KRd or KRd induction achieved longer progression-free survival than those treated with VMP9-Rd9. The median PFS was not reached with Dara-KRd, was 74.1 months with KRd, and 60.4 months with VMP9-Rd9, corresponding to hazard ratios of 0.73 and 0.75 for Dara-KRd and KRd, respectively. No differences in overall survival have been observed to date.

Conclusions:

Maintenance with DR was an effective maintenance strategy after induction and consolidation in FIT transplant-ineligible NDMM, with a trend toward a greater PFS benefit observed in the MRD negative cohort. The less pronounced benefit observed in MRD-positive patients, supports the evaluation of alternative maintenance strategies incorporating novel targets and mechanisms of action.

Maria-Victoria Mateos Jr, MD, PhD: AbbVie - Honoraria; GSK - Honoraria; Roche - Honoraria; Johnson&Johnson - Honoraria; Takeda - Honoraria; Sanofi - Honoraria; Janssen - Honoraria; Oncopeptides - Honoraria; Amgen - Honoraria; Stemline Menarini - Honoraria; Kite - Honoraria; BMS-Celgene - Honoraria; Regeneron - Honoraria; Pfizer - Honoraria; BMS - Honoraria; Eli Lilly and Company - Honoraria; Sanofi - Consultancy (Includes expert testimony); Oncopeptides - Consultancy (Includes expert testimony); Johnson&Johnson - Consultancy (Includes expert testimony); Kite - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Stemline Menarini - Consultancy (Includes expert testimony); Eli Lilly and Company - Consultancy (Includes expert testimony)